Sanofi Appeal Puts Hospira's Generic Eloxatin On Hold
By Ben James ( August 17, 2009, 2:29 PM EDT) -- Hospira Inc.'s efforts to tap into the $1.4 billion annual U.S. market for Sanofi-Aventis' cancer treatment Eloxatin have hit a snag now that the U.S. Food and Drug Administration has suspended its approval of Hospira's generics because of a federal appeals court's order in litigation Sanofi-Aventis brought against the FDA....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.